Your browser doesn't support javascript.
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.
Spencer, Alexandra J; Morris, Susan; Ulaszewska, Marta; Powers, Claire; Kailath, Reshma; Bissett, Cameron; Truby, Adam; Thakur, Nazia; Newman, Joseph; Allen, Elizabeth R; Rudiansyah, Indra; Liu, Chang; Dejnirattisai, Wanwisa; Mongkolsapaya, Juthathip; Davies, Hannah; Donnellan, Francesca R; Pulido, David; Peacock, Thomas P; Barclay, Wendy S; Bright, Helen; Ren, Kuishu; Screaton, Gavin; McTamney, Patrick; Bailey, Dalan; Gilbert, Sarah C; Lambe, Teresa.
  • Spencer AJ; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom. Electronic address: alex.spencer@ndm.ox.ac.uk.
  • Morris S; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Ulaszewska M; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Powers C; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Kailath R; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Bissett C; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Truby A; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Thakur N; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom; The Pirbright Institute, Woking, Surrey, United Kingdom.
  • Newman J; The Pirbright Institute, Woking, Surrey, United Kingdom.
  • Allen ER; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Rudiansyah I; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Liu C; The Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, United Kingdom; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, United Kingdom.
  • Dejnirattisai W; The Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, United Kingdom.
  • Mongkolsapaya J; The Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, United Kingdom.
  • Davies H; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Donnellan FR; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Pulido D; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Peacock TP; Department of Infectious Disease, Imperial College London, United Kingdom.
  • Barclay WS; Department of Infectious Disease, Imperial College London, United Kingdom.
  • Bright H; Virology and Vaccine Discovery, Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD United States.
  • Ren K; Virology and Vaccine Discovery, Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD United States.
  • Screaton G; The Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, United Kingdom.
  • McTamney P; Virology and Vaccine Discovery, Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD United States.
  • Bailey D; The Pirbright Institute, Woking, Surrey, United Kingdom.
  • Gilbert SC; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
  • Lambe T; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, United Kingdom.
EBioMedicine ; 77: 103902, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1700817
ABSTRACT

BACKGROUND:

There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified containing mutations in key proteins.

METHODS:

In this study we describe the generation and preclinical assessment of a ChAdOx1-vectored vaccine (AZD2816) which expresses the spike protein of the Beta VoC (B.1.351).

FINDINGS:

We demonstrate that AZD2816 is immunogenic after a single dose. When AZD2816 is used as a booster dose in animals primed with a vaccine encoding the original spike protein (ChAdOx1 nCoV-19/ [AZD1222]), an increase in binding and neutralising antibodies against Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) is observed following each additional dose. In addition, a strong and polyfunctional T cell response was measured all booster regimens.

INTERPRETATION:

Real world data is demonstrating that one or more doses of licensed SARS-CoV-2 vaccines confer reduced protection against hospitalisation and deaths caused by divergent VoC, including Omicron. Our data support the ongoing clinical development and testing of booster vaccines to increase immunity against highly mutated VoC.

FUNDING:

This research was funded by AstraZeneca with supporting funds from MRC and BBSRC.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: EBioMedicine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: EBioMedicine Year: 2022 Document Type: Article